source
- AstraZeneca halts phase 3 lung cancer trial of bispecific antibody volrustomig after it falls short of KeytrudaAstraZeneca stopped its phase 3 trial of the bispecific antibody volrustomig in metastatic non‑small cell lung cancer after interim data suggested the regimen would not meet the study's primary goa…
- FDA clears Lantheus’ Alzheimer’s PET imaging agent TauklarifyLantheus, which recently agreed to an $8 billion takeover by fellow radiopharma Curium, garnered FDA clearance for its Alzheimer’s PET imaging agent Tauklarify.Fierce Biotech · 5h ago↗ source